AtherosclerosisNCT07080151
Zhongshan Hospital Cardiovascular Imaging Registry
An observational study of Atherosclerosis and Cardiovascular Diseases, run by Shanghai Zhongshan Hospital.
Trial summary
The purpose of this registry is to establish a multi-modality cardiac image database including coronary angiography (CAG), optical coherence tomography (OCT), intravascular ultrasound (IVUS), computed tomography angiograms (CTA) and cardiac magnetic resonance imaging (CMR) for future studies. Read more about this study
- Who is it for?
- Ages 14 to 99 years
- Conditions the study is for
- Atherosclerosis, Cardiovascular Diseases
- What is being tested?
- Cardiac imaging
- How many people
- 10,000 participants
- Where
- No sites listed yet
- Study dates
- 1 Aug 2025to 31 Dec 2045
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 14 to 99 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with potential cardiovascular disease(s) (CVD) or diagnosed with CVD who were referred to CTA and/or CAG at Zhongshan Hospital, Fudan university.
Who may be able to join
- Patients with potential cardiovascular disease(s) (CVD) or diagnosed with CVD who were referred to CTA and/or CAG.
- Optional cardiac imagings, namely OCT/IVUS/CMR were up to doctors in charge and not mandatory.
Who cannot join
- Patient without any of the above mentioned cardiac imaging record.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
The purpose of this registry is to establish a multi-modality cardiac image database including coronary angiography (CAG), optical coherence tomography (OCT), intravascular ultrasound (IVUS), computed tomography angiograms (CTA) and cardiac magnetic resonance imaging (CMR) for future studies. The main goal of this collaboration is to create a resource for advanced research on atherosclerosis through image analysis.
Read the detailed description
This registry plans to establish a multi-modality cardiac image database including coronary angiography (CAG), optical coherence tomography (OCT), intravascular ultrasound (IVUS), computed tomography angiograms (CTA) and cardiac magnetic resonance imaging (CMR) for future studies. Patients who underwent CAG or CTA during Aug 1st, 2025 and Dec 31st, 2035 at Zhongshan Hospital will be included in this registry. In addition, patients with CTA or at least one of OCT/IVUS/CMR between Jan 1st, 2012 and Jul 31st, 2025 will be retrospectively registered. Subgroups of these patients will have OCT/IVUS/CMR as according to their clinical presentations and requests from their doctors in charge. This registry aims to create a resource for advanced imaging research on atherosclerosis.
- Conditions
- Atherosclerosis, Cardiovascular Diseases
- Being tested
- Cardiac imaging
- Keywords
- Computed Tomography Angiography, Coronary Angiography, Intravascular Ultrasound, Optical Coherence Tomography, Cardiac Magnetic Resonance Imaging
- Medical subject headings
- Atherosclerosis, Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cardiac imagingOther
Also called CAG/CTA/OCT/IVUS/CMR
Patients who underwent CTA or CAG, with or without other cardiac imaging modelities (OCT, IVUS, or CMR) will be enrolled in this registry.
| Study group | Role | What they receive |
|---|---|---|
| Study cohort | Patients who underwent CAG or CTA during Aug 1st, 2025 and Dec 31st, 2035 at Zhongshan Hospital will be included in this registry. In addition, patients with CTA or at least one of OCT/IVUS/CMR between Jan 1st, 2012 and Jul 31st, 2025 will be retrospectively registered. Receives: Other: Cardiac imaging |
What is being measured
The primary outcome is the main question the study is designed to answer.
MACE
Major adverse cardiac events
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jul 2025
- Study start1 Aug 2025 (estimated)
- Primary completion31 Dec 2035 (estimated)
- Study completion31 Dec 2045 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AtherosclerosisStudies of the same condition, open and under way.
- More trials run by Shanghai Zhongshan HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Other
- Enrolment
- 10,000 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Shanghai Zhongshan Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Junbo Ge, Shanghai Zhongshan Hospital
- Investigators
- Junbo Ge, MD, PhD, Principal investigator, Cardiovascular Department, Zhongshan Hospital, Fudan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07080151
- Sponsor's protocol ID
- ZSCD2025
- Status last verified
- Jul 2025
- First submitted
- 14 Jul 2025
- Last updated
- 30 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: There is no plan to share IPD for this observational study.
Study at a glance
From the registry record, last updated by the sponsor on 30 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Zhongshan Hospital Cardiovascular Imaging Registry
- ClinicalTrials.gov ID
- NCT07080151
- Acronym / sponsor ID
- ZSCD2025
- Conditions
- Atherosclerosis, Cardiovascular Diseases
- Keywords
- Computed Tomography Angiography, Coronary Angiography, Intravascular Ultrasound, Optical Coherence Tomography, Cardiac Magnetic Resonance Imaging
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 10,000 participants (estimated)
- Lead sponsor
- Shanghai Zhongshan HospitalUniversity, hospital or other
- Study start
- 1 Aug 2025 (estimated)
- Primary completion
- 31 Dec 2035 (estimated)
- Study completion
- 31 Dec 2045 (estimated)
- First posted
- 23 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this registry is to establish a multi-modality cardiac image database including coronary angiography (CAG), optical coherence tomography (OCT), intravascular ultrasound (IVUS), computed tomography angiograms (CTA) and cardiac magnetic resonance imaging (CMR) for future studies. The main goal of this collaboration is to create a resource for advanced research on atherosclerosis through image analysis.
Detailed description
This registry plans to establish a multi-modality cardiac image database including coronary angiography (CAG), optical coherence tomography (OCT), intravascular ultrasound (IVUS), computed tomography angiograms (CTA) and cardiac magnetic resonance imaging (CMR) for future studies. Patients who underwent CAG or CTA during Aug 1st, 2025 and Dec 31st, 2035 at Zhongshan Hospital will be included in this registry. In addition, patients with CTA or at least one of OCT/IVUS/CMR between Jan 1st, 2012 and Jul 31st, 2025 will be retrospectively registered. Subgroups of these patients will have OCT/IVUS/CMR as according to their clinical presentations and requests from their doctors in charge. This registry aims to create a resource for advanced imaging research on atherosclerosis.
Study design
- Observational model
- Other
- Time perspective
- Other
- Target follow-up
- 10 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Study cohort | – | Other: Cardiac imagingPatients who underwent CAG or CTA during Aug 1st, 2025 and Dec 31st, 2035 at Zhongshan Hospital will be included in this registry. In addition, patients with CTA or at least one of OCT/IVUS/CMR between Jan 1st, 2012 and Jul 31st, 2025 will be retrospectively registered. |
Who may qualify
- Ages
- 14 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with potential cardiovascular disease(s) (CVD) or diagnosed with CVD who were referred to CTA and/or CAG at Zhongshan Hospital, Fudan university.
Key inclusion criteria (2 listed)
- Patients with potential cardiovascular disease(s) (CVD) or diagnosed with CVD who were referred to CTA and/or CAG.
- Optional cardiac imagings, namely OCT/IVUS/CMR were up to doctors in charge and not mandatory.
Key exclusion criteria (1 listed)
- Patient without any of the above mentioned cardiac imaging record.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cardiac imagingAlso: CAG/CTA/OCT/IVUS/CMRPatients who underwent CTA or CAG, with or without other cardiac imaging modelities (OCT, IVUS, or CMR) will be enrolled in this registry. | Other | Study cohort |
Primary outcome
MACE
Time frame: 10 years
Major adverse cardiac events
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jul 2025.
- Individual participant dataSharing planned: No. There is no plan to share IPD for this observational study.
Related trials for Atherosclerosis
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Active, not recruiting
SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study
Peripheral Artery Disease
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
RecruitingPhase 3
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
Peripheral Artery Disease (PAD)
Recruiting
The THOR IDE Study
Peripheral Artery Disease, Peripheral Artery Stenosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Junbo Ge, MD, PhD principal investigator
Cardiovascular Department, Zhongshan Hospital, Fudan University
Questions about this trial
What is this clinical trial studying?
An observational study of Atherosclerosis and Cardiovascular Diseases, run by Shanghai Zhongshan Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 30 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Chenguang Li, MD, PhD (8602164041990, li.chenguang@zs-hospital.sh.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MACE (time frame: 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2025.